Pharmacokinetics of dapsone Gel, 5% for the treatment of acne vulgaris

Clinical Pharmacokinetics

Volumn 46, Issue 8, 2007, Pages 697-712

  Thiboutot, Diane M ^a,f   Willmer, Jonathan ^b   Sharata, Harry ^c   Halder, Rebat ^d   Garrett, Steven ^e  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b CANTEST Ltd   (Canada)

^c Madison Skin and Research Inc   (United States)

^d HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e QLT USA Inc   (United States)

^f PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDAPSONE; ACZONE; COTRIMOXAZOLE; DAPSONE; DRUG METABOLITE; N HYDROXYDAPSONE; SULFAMETHOXAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ACNE VULGARIS; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HEMOLYTIC ANEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METHEMOGLOBINEMIA; MONOTHERAPY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RETICULOCYTE COUNT; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CHILD; CROSS-OVER STUDIES; DAPSONE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GELS; HUMANS; LONGITUDINAL STUDIES; MALE; PHARMACOKINETICS;

EID: 34547621610     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746080-00006     Document Type: Article

References (18)

1. Stern RS. Dermatologists and office-based care of dermatologic disease in the 21st century. J Invest Dermatol Symp Proc 2004; 9: 126-30
2. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292: 726-35
3. Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol 2003; 19: 1-10
4. Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol 2000; 142: 1084-91
5. Jeremy AHT, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20-7
6. Jappe U. Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy. Acta Derm Venereol 2003; 83: 241-8
7. Pawin H, Beylot C, Chivot M, et al. Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 2004; 14: 4-12
8. Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin 2001; 19: 79-86
9. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001; 45: 420-34
10. Jacobus Pharmaceutical Co., Inc. Dapsone prescribing information. Princeton (NJ): Jacobus Pharmaceutical Co., Inc, 1997
11. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol 1961; 73: 367-70
12. Prendiville JS, Logan RA, Russell-Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol 1988; 13: 67-71
13. Wolf R, Matz H, Orion E, et al. Dapsone. Dermatol Online J 2002; 8: 2
14. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007 Mar; 56 (3): 439.e1-439.e10
15. Roberts J, Maloney M, Ling M, et al. 5% dapsone topical gel: safety and efficacy with long-term (1 year) treatment for acne vulgaris [abstract]. J Am Acad Dermatol 2005; 52 Suppl.: P5
16. US FDA Center for Drug Evaluation and Research. Guidance for industry: in vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labelling. Rockville (MD): Center for Drug Evaluation and Research, 1999 [online]. Available from URL: http://www.fda.gov/cber/gdlns/metabol.pdf [Accessed 2007 June 28]
17. Zuidema J, Hilbers-Moderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11: 299-315
18. Mitra AK, Thummel KE, Kalhorn TF, et al. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995; 58: 556-66